Analysts are intrested in these 5 stocks: ( (CYTK) ), ( (PRME) ), ( (DOCS) ), ( (WBD) ) and ( (LQDA) ). Here is a breakdown of their recent ratings and the rationale behind them.
Cytokinetics has leapt back onto analysts’ radar after UBS’s Ashwani Verma upgraded the stock to Buy and lifted the price target to $115, signalling confidence that heart drug Myqorzo can be a major growth engine. Verma sees the launch in obstructive hypertrophic cardiomyopathy gaining rapid traction, with doctors expecting Myqorzo’s share of this market to climb sharply over the next few years and non‑obstructive cases adding a second wave of growth.
The analyst now models peak Myqorzo sales at $5.7 billion, well above what he believes is currently priced into the shares, and expects upcoming earnings to highlight this momentum. With a second potential indication in non‑obstructive disease targeted for approval around 2027 and further data on pipeline drug ACACIA due at a key cardiology conference, he argues the stock could outperform as investors reprice Cytokinetics’ long‑term revenue potential.
Prime Medicine is also back in favour after analyst Arthur He upgraded the stock to Buy with a new $8 price target, driven by a key regulatory green light in New Zealand. Health authorities there have cleared a first‑in‑human trial for PM577a, an in vivo prime editing therapy aimed at Wilson’s disease patients carrying a common ATP7B mutation, marking the company’s transition from preclinical promise to the clinic.
The upcoming Phase 1/2 trial will start with adults who are stable on standard treatment and gradually test higher doses, with management expecting even low doses to show biological activity. The study will use detailed copper‑related biomarkers and withdrawal of standard therapy to test whether PM577a can normalize copper metabolism, and He believes the initial data expected in 2027 could be enough to shift investor sentiment if early results across a handful of patients look reasonably strong.
Doximity, by contrast, is facing a tougher crowd as Bank of America’s Allen Lutz cut the stock to Sell, setting a $20 price objective just below where shares now trade. While he credits the company as a leader in digital pharma advertising and highlights its new AI assistant DoxGPT, he questions how much further it can grow budgets from big drugmakers that already spend heavily on the platform.
Lutz warns that Doximity’s pivot toward AI brings both higher investment needs and stiff competition from well‑funded rivals, potentially putting long‑standing profit margins near 50% under pressure. With management also navigating leadership changes and possible pricing concessions to maintain growth, he believes investors may be underestimating the risk that earnings fall short of current expectations even though the stock looks inexpensive on traditional metrics.
Warner Bros. Discovery has drawn fresh buy‑side optimism after Seaport Research’s David Joyce upgraded the media group to Buy with a $31 price target tied to its planned cash sale to Paramount Skydance. Joyce argues that, while the company is “not out of the woods,” the odds of the deal closing appear to be improving as global regulators review the transaction and any required conditions seem manageable.
He notes that authorities may push for remedies such as unwinding a European theatrical distribution venture or even selling CNN, but sees these as potentially workable trade‑offs in exchange for closing the deal. For investors, the upgrade frames WBD shares as a tactical opportunity: if the acquisition proceeds as outlined, today’s price offers notable upside to the proposed cash consideration, though timing and U.S. state‑level political risk remain important swing factors.
Liquidia Technologies is another case where success has caught up with valuation, prompting Bank of America’s Jason Gerberry to lower his rating to Hold even as he raised the price target to $79. The company’s inhaled therapy Yutrepia has been a standout launch, quickly amassing thousands of prescriptions and patients since its 2025 debut and positioning itself as a strong alternative to established drug Tyvaso.
Gerberry has increased his peak sales estimate for Yutrepia to $2.2 billion and still expects the drug to hit $1 billion in annual revenue by 2027, but he sees the risk‑reward balance as less compelling after a sharp run‑up in the share price. The key unknown is the outcome of ongoing patent litigation around expanding Yutrepia’s label to a new lung disease indication, with the analyst outlining scenarios that could either shave meaningful value from his forecasts or add roughly 20% upside depending on how the court rules, leaving investors waiting for legal clarity before betting on further gains.


